Touch device users, explore by touch or with swipe gestures. Caladrius Biosciences, Inc. (NASDAQ:CLBS) was the recipient of some unusual options trading on Wednesday. Caladrius Biosciences Inc. analyst ratings, historical stock prices, earnings estimates & actuals. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Their average twelve-month price target is $9.00, predicting that the stock has a possible upside of 260.00%. The company’s stock price has collected 2.52% of gains in the last five trading sessions. CLBS updated stock price target summary. CLBS: Caladrius Biosciences, Inc. broker reports. Get the latest Caladrius Biosciences (CLBS) stock price quote with real-time news, financials, charts and other important investing information. MarketBeat just released five new trading ideas, but Caladrius Biosciences wasn't one of … Shares of CLBS traded up $2.23 during mid-day trading on Wednesday, reaching $3.86. var dom1 = document.querySelector('#form1783 #field1');var field1 = new LiveValidation(dom1, {validMessage: "", onlyOnBlur: false, wait: 300});field1.add(Validate.Presence, {failureMessage:"This field is required"});field1.add(Validate.Format, {pattern: /(^[A-Z0-9!#$%&'\*\+\-\/=\?\^_`\{\|\}~][A-Z0-9!#$%&'\*\+\-\/=\?\^_`\{\|\}~\.]{0,62}@(([A-Z0-9](?:[A-Z0-9\-]{0,61}[A-Z0-9])?)(\.[A-Z0-9](?:[A-Z0-9\-]{0,61}[A-Z0-9])? In the clinical stage, the company has no approved products to sell, and therefore, doesn’t earn revenue from the sale of its treatments. ... Analyst Recommendation 1/19/2021 Buy 1 Year Price Target. Caladrius Biosciences, Inc. (CLBS) projections and forecasts. Caladrius Biosciences shares last traded at $4.12, with a volume of 965,227 shares traded. Caladrius Biosciences, Inc. earnings are expected to decrease by -12.4% in 2021, but the outlook is negative 0% per year for the next five years. Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Stay up to date with lastest Earnings Announcements for Caladrius Biosciences, Inc. from Zacks Investment Research Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes … The 12-month stock price forecast is 6.50, which is an increase of 124.91% from the latest price. CLBS: Caladrius Biosciences, Inc. - Earnings Announcements. When autocomplete results are available use up and down arrows to review and enter to select. That average ranking earns Caladrius Biosciences Inc an Analyst Rating of 61, which is better than 61% of stocks based on data compiled by … Please note that any opinions, estimates or forecasts regarding Caladrius’ performance made by analysts are theirs alone and do not represent the opinions, tadalafiltablets forecasts or predictions of Caladrius or its management. Location*Please select…United StatesAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, the Democratic Republic of theCook IslandsCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, the former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesia, Federated States ofMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian Territory, OccupiedPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarReunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States Minor Outlying IslandsUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet NamVirgin Islands (British)Virgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabwe. Caladrius is providing this list as a service to its shareowners, and does not by listing these firms imply its endorsement of or concurrence with their information, conclusions or recommendations. Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective (down previously […] @/i, failureMessage: "A valid email address is required", negate: "true"});var dom2 = document.querySelector('#form1783 #field2');var field2 = new LiveValidation(dom2, {validMessage: "", onlyOnBlur: false, wait: 300});field2.add(Validate.Presence, {failureMessage:"This field is required"});var dom5 = document.querySelector('#form1783 #field5');var field5 = new LiveValidation(dom5, {validMessage: "", onlyOnBlur: false, wait: 300});field5.add(Validate.Custom, {against: function(value) {return !value.match(/(telnet|ftp|https?):\/\/(?:[a-z0-9][a-z0-9-]{0,61}[a-z0-9]\.|[a-z0-9]\. Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. When Caladrius Biosciences last reported its balance sheet in June 2020, it had zero debt and cash worth US$35m. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. 110 Allen Road, 2nd Floor Basking Ridge, NJ 07920 Tel: 908.842.0100. Create your Watchlist to save your favorite quotes on Nasdaq.com. Caladrius Biosciences, Inc. (NASDAQ:CLBS)’s stock price gapped up before the market opened on Wednesday . Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. This list is subject to change as firms add or delete coverage of the company. with a high estimate of $0.00 Wall Street is positive on Caladrius Biosciences Inc ( CLBS ). Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Caladrius Biosciences (New York) 800 Westchester Avenue Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. About Caladrius Biosciences. Find the latest analyst research for Caladrius Biosciences, Inc. Common Stock (CLBS) at Nasdaq.com. H.C. Wainwright analyst Joseph Pantginis initiated coverage with a Buy rating on Caladrius Biosciences (CLBS – Research Report) today and set a price target of $14.00.The company’s shares closed last Tuesday at $1.59. In-depth view of key statistics and finances for CALADRIUS BIOSCIENCES, INC. (CLBS) on MSN Money. On average, analysts give Caladrius Biosciences Inc a Strong Buy rating. msn back to msn home money. I would like to receive Nasdaq communications related to Products, Industry News and Events.You can always change your preferences or unsubscribe and your contact information is covered by our Privacy Policy. Wall Street analysts have given Caladrius Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Investors purchased 6,571 call options on the stock. Get the latest broker reports from Zacks Investment Research. According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 40.9% and a 67.1% success rate. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases. Earnings vs Savings Rate: CLBS is forecast to remain unprofitable over the next 3 years. These symbols will be available throughout the site during your session. Analyst Ratings Caladrius Biosciences (NASDAQ:CLBS) Price Target and Consensus Rating 4 Wall Street analysts have issued ratings and price targets for Caladrius Biosciences in the last 12 months. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Caladrius Biosciences Inc. (NASDAQ:CLBS) went up by 162.57% from its latest closing price compared to the recent 1-year high of $3.21. Analyst price targets provided by TipRanks. Yes! The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. The stock had previously closed at $1.63, but opened at $3.48. This represents an increase of approximately 3,882% compared to the typical daily volume of 165 call options. Caladrius Biosciences is currently followed by the analysts listed below. Profitability This table compares Caladrius Biosciences and BioRestorative Therapies’ net margins, return on … Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease